跳至主要内容
临床试验/NCT06735196
NCT06735196已完成不适用

Profiling the Variation of Microbiome Along the Intestinal Tract Based on Sampling Capsule Endoscopy: a Feasibility and Safety Study

Changhai Hospital1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2024年12月30日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
30
试验地点
1
主要终点
The feasibility of sampling capsule endoscopy system in collecting fluids from different intestinal segments in healthy volunteers

研究概览

简要总结

Intestinal flora and metabolites are associated with multiple systemic diseases. Current approaches for acquiring information regarding microbiota/metabolites have limitations. We aimed to develop a precise sampling capsule endoscopy (SCE) for the convenient, non-invasive, and accurate acquisition of digestive bioinformation for disease diagnosis and evaluation. The SCE was used for sampling jejunum, ileum, and colon content in healthy volunteers. The GI liquid was then used for microbiome profiling and metabolomics profiling. In this study, we aimed to describe the characteristics and functions of key microflora in the whole intestinal microenvironment of healthy volunteers.

详细描述

Gut microorganisms involved in human food digestion, immune system regulation, and protection against pathogens are critical in maintaining health. Gut microorganism dysbiosis influences the course of gastrointestinal disease and cardiovascular, neurological, metabolic diseases, and other disorders. Therefore, a deeper understanding of gut microorganisms is indispensable in researching human disorders. However, current sampling methods, including fecal microbial examination, breath hydrogen testing, and invasive endoscopy acquisition, fail to obtain local gut microbiome samples under its chemical environment in natural and unperturbed states. A comfortable, non-invasive, and precise regional intestinal fluid collection device is needed.

Recently, novel ingestible devices have collected intestinal fluids from animals' and humans' jejunum, ileum, and colon. Significant differences between bacteria and metabolites in the intestines versus stool have been identified, showing the spatiotemporal structure of the gastrointestinal microbiome and metabolome. Compared with saliva and stool samples, ingestible devices acquired samples in an environment resembling nature, which is more reliable in explaining the association between gut microorganisms dysbiosis and various disorders.

However, current ingestible sampling devices still have several limitations. Therefore, a novel sampling capsule endoscopy (SCE) system was developed. This novel SCE can precisely and efficiently acquire intestinal bio information through direct visualization under electric control. This study aims to collect fluids from different segments of the gastrointestinal tract using the SCE system to clarify the differences in the distribution of gut microorganisms in different areas in healthy volunteers and patients with inflammatory bowel disease or colon cancer.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Male or female, age ≥18 years and ≤80 years;
  • •American Society of Anesthesiologists (ASA) physical health risk level 1;
  • •Good overall health, no clinically significant medical history;
  • •No clinically significant signs were found in the physical examination;
  • •For women of fertility, the urine pregnancy test was negative within 7 days after the screening visit, and they were willing to take contraceptive measures throughout the study;
  • •Willing to provide blood samples, stool samples, urine samples, saliva samples, and intestinal fluid samples, and agree that the samples provided will be stored for a long time and used for research purposes.
  • •Agree to avoid strenuous activities during the participation in this clinical trial;
  • •Agree to participate in this clinical trial and sign the informed consent form.

排除标准

  • •Patients with digestive tract diseases such as cancer, inflammatory bowel disease, achalasia, esophageal diverticulum, etc.;
  • •Patients who have participated in other clinical trials within three months or are currently participating in other clinical trials;
  • •Patients currently use medication for other diseases or plan to use medication for treatment;
  • •Patients who have used antibiotics within three months;
  • •Patients with known or suspected gastrointestinal obstruction, stenosis, diverticulum, and fistula;
  • •Patients with swallowing disorders;
  • •Pregnant or lactating women or women who plan to become pregnant within 30 days of the visit period;
  • •Patients who are not suitable for surgery or refuse to undergo any abdominal surgery (once the capsule is retained, it cannot be removed by surgery);
  • •Patients with any form of active substance abuse or dependence (including drug or alcohol abuse), any unstable physical or mental illness, any malignant lesions in any location or system, or any chronic disease that the researcher believes may interfere with the study;
  • •The researcher believes any other factors are unsuitable for selection or affect the subject's participation in the study.

研究组 & 干预措施

Healthy volunteers

Other

After standard gastrointestinal preparation, healthy volunteers swallowed SCEs to collect intestinal fluids in different intestinal areas.

干预措施: sampling capsule endoscopy (Device)

结局指标

主要结局

The feasibility of sampling capsule endoscopy system in collecting fluids from different intestinal segments in healthy volunteers

时间窗: two weeks

The total successful rate of SCE in sampling fluids in intestinal segments. A successful sampling procedure conducted by SCE was defined when the following conditions were met simultaneously: 1) accurately recognization of target intestinal areas. 2) the intestinal liquid can be successfully collected in the sampling chamber.

次要结局

  • Standard gastrointestinal preparation procedure(two week)
  • Sampling time(two weeks)
  • Sampling volume(two weeks)
  • Number of sampling times(two weeks)
  • Safety analysis(from enrollment to the end of follow-up at 30 days)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Zhuan Liao

Clinical Professor

Changhai Hospital

研究点 (1)

Loading locations...

相似试验